Jordi Bover

List of Publications by Year in Descending Order

79 papers	1,551 citations	21 h-index	36 g-index
87 ext. papers	1,959 ext. citations	3.9 avg, IF	4.65 L-index

#	Paper	IF	Citations
79	Osteoporosis in chronic kidney disease: A essential challenge. *Medicina Clínica (English Edition)*, **2022**, 158, 27-34	0.3	
78	Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease. *Nefrologia*, **2021**, 41, 514-528	0.4	0
77	Sobre la amplia difusión y autoría de «los riñones también hablan español». *Nefrologia*, **2021**,	1.5	
76	Documento de información y consenso para la detección y manejo de la enfermedad renal crónica. *Nefrologia*, **2021**,	1.5	1
75	Kidneys also speak Spanish. *Nefrologia*, **2021**, 41, 224-226	0.4	
74	Kidneys also speak Spanish. *Nefrologia*, **2021**, 41, 225-226	1.5	4
73	The Use of Imaging Techniques in Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD)-A Systematic Review. *Diagnostics*, **2021**, 11,	3.8	5
72	Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 16, 736-745	6.9	3
71	Clinical Approach to Vascular Calcification in Patients With Non-dialysis Dependent Chronic Kidney Disease: Mineral-Bone Disorder-Related Aspects. *Frontiers in Medicine*, **2021**, 8, 642718	4.9	3
70	Osteoporosis in chronic kidney disease: A essential challenge. *Medicina Clínica*, **2021**, 158, 27-27	1	1
69	Bisphenol a Exposure and Kidney Diseases: Systematic Review, Meta-Analysis, and NHANES 03-16 Study. *Biomolecules*, **2021**, 11,	5.9	3
68	Control of phosphorus and prevention of fractures in the kidney patient. *Nefrologia*, **2021**, 41, 7-14	1.5	2
67	Bone Fragility Fractures in CKD Patients. *Calcified Tissue International*, **2021**, 108, 539-550	3.9	9
66	Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification. *CKJ: Clinical Kidney Journal*, **2021**, 14, 366-374	4.5	4
65	The Non-invasive Diagnosis of Bone Disorders in CKD. *Calcified Tissue International*, **2021**, 108, 512-527	3.9	7
64	Control of phosphorus and prevention of fractures in the kidney patient. *Nefrologia*, **2021**, 41, 7-14	0.4	
63	Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. *Nefrologia*, **2021**, 42, 223-223	1.5	0

62	Hiporrespuesta o resistencia a la acci□ de la hormona paratiroidea en la enfermedad renal cr□ica. *Nefrologia*, **2021**, 41, 514-528	1.5	2
61	Acute Renal Failure Secondary to an Unusual Familial Metabolic Myopathy. *Nephron*, **2021**, 145, 199-204	3.3	0
60	Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial. *Kidney International Reports*, **2020**, 5, 2178-2182	4.1	4
59	Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3-5 Not on Dialysis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
58	Bone, inflammation and chronic kidney disease. *Clinica Chimica Acta*, **2020**, 506, 236-240	6.2	10
57	PTH Receptors and Skeletal Resistance to PTH Action **2020**, 51-77		2
56	Relation Between PTH and Biochemical Markers of MBD **2020**, 103-116		1
55	Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study. *Circulation*, **2020**, 141, 728-739	16.7	53
54	New information on phosphate binder interactions with vitamin K. *Nefrologia*, **2020**, 40, 369-370	1.5	
53	New information on phosphate binder interactions with vitamin K. *Nefrologia*, **2020**, 40, 369-370	0.4	
52	English-Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?. *Kidney International*, **2020**, 98, 1352-1353	9.9	6
51	Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait?. *CKJ: Clinical Kidney Journal*, **2020**, 13, 513-521	4.5	13
50	Valvular heart disease and calcification in CKD: more common than appreciated. *Nephrology Dialysis Transplantation*, **2020**, 35, 2046-2053	4.3	20
49	Small steps towards the potential of \preventiveVtreatment of early phosphate loading in chronic kidney disease patients. *CKJ: Clinical Kidney Journal*, **2019**, 12, 673-677	4.5	3
48	Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. *Nefrologia*, **2019**, 39, 227-242	0.4	8
47	Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. *Nefrologia*, **2019**, 39, 227-242	1.5	16
46	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. *CKJ: Clinical Kidney Journal*, **2019**, 12, 269-280	4.5	18
45	Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders. *Calcified Tissue International*, **2018**, 103, 111-124	3.9	34

44	Bone, inflammation and the bone marrow niche in chronic kidney disease: what do we know?. *Nephrology Dialysis Transplantation*, **2018**, 33, 2092-2100	4.3	19
43	Osteoporosis, bone mineral density and CKD-MBD complex (I): Diagnostic considerations. *Nefrologia*, **2018**, 38, 476-490	1.5	20
42	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 319-331	18.1	67
41	Osteoporosis, bone mineral density and CKD-MBD complex (I): Diagnostic considerations. *Nefrologia*, **2018**, 38, 476-490	0.4	10
40	Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. *Journal of Nephrology*, **2017**, 30, 677-687	4.8	38
39	Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study. *International Urology and Nephrology*, **2017**, 49, 689-700	2.3	1
38	Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. *Kidney International*, **2017**, 92, 1343-1355	9.9	97
37	Vitamin D, a modulator of musculoskeletal health in chronic kidney disease. *Journal of Cachexia, Sarcopenia and Muscle*, **2017**, 8, 686-701	10.3	52
36	Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 161-74	6.9	41
35	Detection of cardiovascular calcifications: Is it a useful tool for nephrologists?. *Nefrologia*, **2016**, 36, 587-596	1.5	11
34	Parathyroid hormone metabolism and signaling in health and chronic kidney disease. *Kidney International*, **2016**, 90, 1184-1190	9.9	80
33	Vitamin D Receptor and Interaction with DNA: From Physiology to Chronic Kidney Disease **2016**, 75-116		2
32	What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?. *World Journal of Nephrology*, **2016**, 5, 471-81	3.6	17
31	The Parathyroid Type I Receptor and Vitamin D in Chronic Kidney Disease **2016**, 163-177		1
30	Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications. *Nefrologia*, **2016**, 36, 597-608	0.4	13
29	Magnesium-based interventions for normal kidney function and chronic kidney disease. *Magnesium Research*, **2016**, 29, 126-140	1.7	14
28	Detection of cardiovascular calcifications: Is it a useful tool for nephrologists?. *Nefrologia*, **2016**, 36, 587-596	0.4	5
27	Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications. *Nefrologia*, **2016**, 36, 597-608	1.5	17

26	Pro: cardiovascular calcifications are clinically relevant. *Nephrology Dialysis Transplantation*, **2015**, 30, 345-51	4.3	46
25	Opponent\¥ comments. *Nephrology Dialysis Transplantation*, **2015**, 30, 357	4.3	6
24	Vascular calcification in patients with nondialysis CKD over 3 years. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 654-66	6.9	93
23	Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease. *Nefrologia*, **2015**, 35, 28-41	1.5	23
22	Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. *Nephrology Dialysis Transplantation*, **2014**, 29, 1815-20	4.3	77
21	Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 427-36	18.1	102
20	News on biomarkers in CKD-MBD. *Seminars in Nephrology*, **2014**, 34, 598-611	4.8	33
19	When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. *Seminars in Nephrology*, **2014**, 34, 612-25	4.8	45
18	Adynamic bone disease: from bone to vessels in chronic kidney disease. *Seminars in Nephrology*, **2014**, 34, 626-40	4.8	82
17	Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol). *Current Vascular Pharmacology*, **2014**, 12, 313-23	3.3	11
16	Tables for estimating the glomerular filtration rate using the new CKD-EPI equation from serum creatinine concentration. *Nefrologia*, **2014**, 34, 223-9	1.5	6
15	Recombinant PTH associated with hypercalcaemia and renal failure. *CKJ: Clinical Kidney Journal*, **2013**, 6, 93-95	4.5	4
14	Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence. *Patient Preference and Adherence* , **2013**, 7, 1147-56	2.4	9
13	The Modification of Diet in Renal Disease 4-calculated glomerular filtration rate is a better prognostic factor of cardiovascular events than classical cardiovascular risk factors in patients with peripheral arterial disease. *Journal of Vascular Surgery*, **2012**, 56, 1324-30	3.5	12
12	2010 - Gu□ de pr□tica cl□nica de la Sociedad Espa□ola de Di□lisis y Trasplante de las alteraciones del metabolismo mineral y □seo de la enfermedad renal cr□nica (CKD-MBD). *Dialisis Y Trasplante*, **2011**, 32, 108-118		6
11	Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice. *Nephron Clinical Practice*, **2011**, 118, c109-21		10
10	Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation. *Kidney International Supplements*, **2011**, 1, 122-129	6.3	23
9	Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). *Nefrologia*, **2011**, 31 Suppl 1, 3-32	1.5	19

8	Calcimimetics in the chronic kidney disease-mineral and bone disorder. *International Journal of Artificial Organs*, **2009**, 32, 108-21	1.9	12
7	Update on the treatment of chronic kidney disease-mineral and bone disorder. *Journal of Renal Care*, **2009**, 35 Suppl 1, 19-27	1.6	10
6	Diagnostic procedures and rationale for specific therapies in chronic kidney disease-mineral and bone disorder. *Contributions To Nephrology*, **2008**, 161, 222-233	1.6	4
5	Is albuminuria a marker of arterial remodeling?. *Journal of Hypertension*, **2008**, 26, 633-5	1.9	5
4	Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease. *Kidney International*, **2000**, 58, 1023-32	9.9	32
3	Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. *Kidney International*, **1995**, 47, 1746-51	9.9	22
2	Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. *Kidney International*, **1994**, 45, 953-61	9.9	51
1	The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia. *Kidney International*, **1994**, 46, 310-7	9.9	31